组蛋白
细胞生物学
染色质
生物
细胞
化学
组蛋白H3
作者
Cristina Morales Torres,Mary Y. Wu,Sebastijan Hobor,Elanor N. Wainwright,Matthew J. Martin,Harshil Patel,William Grey,Eva Grönroos,Steven Howell,Joana Carvalho,Ambrosius P. Snijders,Michael Bustin,Dominique Bonnet,Paul D. Smith,Charles Swanton,Michael Howell,Paola Scaffidi
标识
DOI:10.1038/s41467-020-15615-z
摘要
Continuous cancer growth is driven by subsets of self-renewing malignant cells. Targeting of uncontrolled self-renewal through inhibition of stem cell-related signaling pathways has proven challenging. Here, we show that cancer cells can be selectively deprived of self-renewal ability by interfering with their epigenetic state. Re-expression of histone H1.0, a tumor-suppressive factor that inhibits cancer cell self-renewal in many cancer types, can be broadly induced by the clinically well-tolerated compound Quisinostat. Through H1.0, Quisinostat inhibits cancer cell self-renewal and halts tumor maintenance without affecting normal stem cell function. Quisinostat also hinders expansion of cells surviving targeted therapy, independently of the cancer types and the resistance mechanism, and inhibits disease relapse in mouse models of lung cancer. Our results identify H1.0 as a major mediator of Quisinostat’s antitumor effect and suggest that sequential administration of targeted therapy and Quisinostat may be a broadly applicable strategy to induce a prolonged response in patients. Targeting self-renewing cancer cells without deleterious side effects in normal tissues has proven challenging. Here, the authors show that the well-tolerated HDAC inhibitor Quisinostat safely inhibits tumor maintenance and disease relapse by restoring high levels of histone H1.0.
科研通智能强力驱动
Strongly Powered by AbleSci AI